FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)

Relapsed/Refractory B-Cell Lymphoma Clinical Trial

Official title:
A Phase 1 Study of FT522 in Combination With Rituximab in Participants With Relapsed/Refractory B-Cell Lymphoma

Status Recruiting

Clinical Trial Summary

This is a phase 1 study of FT522 administered with rituximab in participants with relapsed/refractory B-cell lymphoma (R/R BCL). The primary objectives of the study are to evaluate the safety and tolerability of FT522 in combination with rituximab, and to determine the recommended phase 2 dose (RP2D) of FT522 in combination with rituximab; each objective will be assessed with or without conditioning chemotherapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Lymphoma
Lymphoma, B-Cell
Relapsed/Refractory B-Cell Lymphoma

Clinical Trial Details

NCT number	NCT05950334
Study type	Interventional
Source	Fate Therapeutics
Contact	Fate Trial Disclosure
Phone	866-875-1800
Email	FateTrialDisclosure@fatetherapeutics.com
Status	Recruiting
Phase	Phase 1
Start date	November 16, 2023
Completion date	June 30, 2044

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03156101` - A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects	Phase 1/Phase 2
Completed	`NCT01766583` - A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma	Phase 1
Recruiting	`NCT06445517` - Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma	Phase 1